Ramipril treatment in a patient with glycogen storage disease I non-A

M L Giannì; M Bonvissuto; M Gallieni; C Testolin; E Racchi; E Riva

doi:10.1023/a:1021263504104

Ramipril treatment in a patient with glycogen storage disease I non-A

J Inherit Metab Dis. 2002 Oct;25(6):515-6. doi: 10.1023/a:1021263504104.

Authors

M L Giannì¹, M Bonvissuto, M Gallieni, C Testolin, E Racchi, E Riva

Affiliation

¹ Department of Pediatrics, University of Milan, San Paolo Hospital, Milan, Italy. marialorella.gianni@tin.it

PMID: 12555944
DOI: 10.1023/a:1021263504104

Abstract

We studied the effect of ramipril on proteinuria and mild hypertension in a 21-year-old patient affected by glycogen storage disease type I non-A. After few months of therapy we obtained a decrease in total urine protein excretion that later re-increased in spite of the high dose of ACE inhibitor. Even if ACE inhibitors are the only effective therapy for GSD I nephropathy, further studies are requested.

Publication types

Case Reports

MeSH terms

Adult
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Glucose-6-Phosphatase / genetics
Glycogen Storage Disease Type I / drug therapy*
Glycogen Storage Disease Type I / enzymology
Glycogen Storage Disease Type I / genetics
Humans
Hypertension, Renal / drug therapy
Hypertension, Renal / genetics
Kidney Diseases / drug therapy
Kidney Diseases / genetics
Male
Proteinuria / complications
Ramipril / therapeutic use*

Substances

Angiotensin-Converting Enzyme Inhibitors
Glucose-6-Phosphatase
Ramipril